Biomedical Engineering Reference
In-Depth Information
Distant metastasis-free survival
(DMFS)
Overall survival (OS)
Median
follow-
up
(years)
Good
prognostic
signature
Poor
prognostic
signature
Hazard
ratio
(HR)
Good
prognostic
signature
Poor
prognostic
signature
Hazard
ratio
(HR)
Period of
specimen
collection
First author
(year)
Patient
population
No. of
patients
Age of
patient
Histopathology
Mayordomo
(2008)
Spain
2006-2008
35
all ages
T2-T3 (Core
needle biopsy)
N.A.
n
= 4
n
= 31
Wittner
(2008)
US
1985-1997
100
median
age 63
pT1-T3, pN0
11.3
n
= 27
n
= 73
(5y) 93%
(5y) 51%
N.A.
85%
52%
N.A
(10y) 75%
(10y) 72%
N.A.
N.A.
N.A.
N.A
Mook (2008)
European
1994-2001
241
<71
T1-T3, N1-N3
7.8
n
= 99
n
= 142
(5y) 98 ± 2%
(5y) 80 ± 4%
N.A.
(5y) BCSS 96
± 2%
(5y) BCSS 76
± 4%
BCSS HR
5.7; 95% CI
2.01-16.23;
P
= 0.001
(10y) 91
± 4%
(10y) 76
± 4%
HR 4.13;
95% CI
1.72-
9.96;
(10y) BCSS
99 ± 1%
(10y) BCSS
88 ± 3%
(Overall) HR
5.4; 95% CI
2.11-13.8;
P
P
=
< 0.001
0.002
Mook (2008)
Dutch
1984-1996
148
<71
T1-T2, N0
12.5
n
= 91
n
= 57
(
Continued
)
